Imagine a GPS for surgeons that lets them see exactly where a tumor is in real-time while they treat it. Instead of large surgeries, they use tiny needles and tubes to deliver medicine or heat directly to the cancer. This makes the process faster, safer, and much easier for the patient to recover from.
Current cancer treatments often rely on invasive surgeries or high-dose systemic drugs that cause severe side effects and long recovery times. There is a lack of integrated, real-time imaging to guide minimally invasive tools precisely to the tumor.
A hybrid C-arm prototype and supporting software for radioembolization, along with four multimodal care pathways for liver, lung, and sarcoma cancers.
If you are an imaging hardware provider dealing with low clinical adoption of hybrid systems — this project developed a hybrid C-arm prototype and software that improves the precision of radioembolization for liver cancer.
If you are a drug developer dealing with the toxicity of systemic chemotherapy — this project developed localized drug delivery strategies that allow for a high therapeutic dose while reducing systemic side effects.
If you are a clinic dealing with high patient visit counts and long recovery times — this project developed multimodal care pathways for liver, lung, and sarcoma that accelerate recovery and reduce complication rates.
Based on available project data, specific pricing is not mentioned, but the project aims to create 'affordable care pathways' to reduce the overall burden on the healthcare system.
The project is currently maturing technology from pre-clinical developments to clinical trials, including the testing of a hybrid C-arm prototype, indicating it is moving toward industrial scale.
Based on available project data, specific licensing terms are not provided, but the project is coordinated by Philips Medical Systems Nederland BV with 17 industry partners.
It integrates by providing multimodal imaging (X-ray, ultrasound, CT, MRI) to guide miniaturized instruments, replacing invasive surgical approaches with minimally invasive access.
The project runs from 2023-05-01 to 2027-04-30, with the goal of generating early evidence through clinical studies to enable massive clinical roll-out.
The consortium is heavily weighted toward commercialization, with 17 industry partners (47% of the total) and 7 SMEs. Led by a major global player, Philips Medical Systems, the 36-partner group spans 11 countries, combining academic research from 11 universities with industrial scale to move prototypes into clinical practice.
Contact Philips Medical Systems Nederland BV regarding the IMAGIO project
Contact us to explore licensing opportunities for interventional oncology imaging.
